Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Wedbush increased their FY2020 earnings estimates for shares of Intercept Pharmaceuticals in a report released on Monday. Wedbush analyst L. Moussatos now expects that the biopharmaceutical company will post earnings of $9.57 per share for the year, up from their previous estimate of $9.28. Wedbush currently has a “Buy” rating on the stock.
Several other analysts also recently commented on ICPT. Oppenheimer Holdings, Inc. reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, April 12th. Cowen and Company reiterated a “buy” rating and issued a $225.00 target price on shares of Intercept Pharmaceuticals in a report on Monday, April 24th. Zacks Investment Research downgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 1st. Cantor Fitzgerald set a $60.00 target price on shares of Intercept Pharmaceuticals and gave the company a “sell” rating in a report on Thursday, May 4th. Finally, Laidlaw upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 target price for the company in a report on Friday, May 5th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $196.39.
Shares of Intercept Pharmaceuticals (NASDAQ ICPT) traded down 5.20% on Wednesday, hitting $105.00. 1,048,789 shares of the stock were exchanged. Intercept Pharmaceuticals has a 1-year low of $96.63 and a 1-year high of $177.93. The stock’s 50-day moving average is $124.94 and its 200-day moving average is $118.29. The stock’s market cap is $2.63 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating analysts’ consensus estimates of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 119.17%. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same quarter last year, the firm posted ($3.14) EPS. The company’s quarterly revenue was up 459.6% on a year-over-year basis.
In other Intercept Pharmaceuticals news, insider Lisa Bright sold 698 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $110.73, for a total transaction of $77,289.54. Following the completion of the transaction, the insider now owns 24,711 shares in the company, valued at $2,736,249.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel G. Welch sold 217 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $126.76, for a total transaction of $27,506.92. Following the transaction, the director now owns 3,710 shares of the company’s stock, valued at approximately $470,279.60. The disclosure for this sale can be found here. Insiders have sold 45,583 shares of company stock valued at $5,905,154 in the last quarter. Company insiders own 4.50% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares in the last quarter. US Bancorp DE acquired a new position in shares of Intercept Pharmaceuticals during the first quarter worth $130,000. IFP Advisors Inc raised its position in shares of Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 730 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Intercept Pharmaceuticals during the first quarter worth $170,000. Finally, Pacer Advisors Inc. raised its position in shares of Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 330 shares in the last quarter. Hedge funds and other institutional investors own 84.27% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.